The FDA recently approved Egaten for the treatment of patients aged 6 years or older with fascioliasis in the United States, according to a press release.

Fascioliasis, or liver fluke infestation, is caused by ingestion of food or water contaminated with parasitic flatworm larvae and is estimated to affect 2.4 million people around the world. An additional 180 million people are at increased risk for infection.